Prostate cancer: 1HMRS-DCEMR at 3 T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP)

European Journal of Radiology

Volumn 81, Issue 4, 2012, Pages 700-708

  Panebianco, Valeria ^a   Sciarra, Alessandro ^a   Lisi, Danilo ^a   Galati, Francesca ^a   Buonocore, Valeria ^a   Catalano, Carlo ^a   Gentile, Vincenzo ^a   Laghi, Andrea ^a   Passariello, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

18F Choline PET CT; MR 3 T magnet; MR spectroscopy; Prostate cancer; Radical prostatectomy

Indexed keywords

CHOLINE; CITRIC ACID; DIATRIZOATE; GADOBUTROL; GADOLINIUM CHELATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; IMAGE QUALITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RADICAL RETROPUBIC PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

AGED; CHOLINE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTONS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84858287835     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.01.095     Document Type: Article

References (37)

1. C.R. Pound, M.K. Brawer, and A.W. Partin Evaluation and treatment of men with biochemical prestate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer Rev Urol 3 2001 72 84
2. J.F. Ward, and J.W. Moul Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer Curr Opin Urol 15 2005 181 186 (Pubitemid 40586178)
3. J.F. Ward, T.J. Sebo, M.L. Blute, and H. Zincke Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes J Urol 173 2005 1156 1160 (Pubitemid 40380523)
4. S.J. Freedland, M.E. Sutter, F. Dorey, and W.J. Aronson Defining the ideal cutpoint for determiningPSA recurrence after radical prostatectomy prostatespecific antigen Urology 61 2003 365 369 (Pubitemid 36206534)
5. Guidelines on prostate cancer 2009 European Association of Urology
6. D. Loblaw, D.S. Mendelson, and J.A. Talcott American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 2004 2927 2941 (Pubitemid 41079913)
7. A.W. Partin, J.D. Pearson, and P.K. Landis Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases Urology 43 1994 649 659 (Pubitemid 24145607)
8. S.S. Gambhir, J. Czernin, and J. Schwimmer A tabulated summary of the FDG PET literature J Nucl Med 42 Suppl 5 2001 1S 93S (Pubitemid 32423895)
9. T.R. DeGrado, S.W. Baldwin, and S. Wang Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers J Nucl Med 42 2001 1805 1814 (Pubitemid 34016349)
10. T. Hara, N. Kosaka, and H. Kishi Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 2002 187 199 (Pubitemid 34151041)
11. S. Jana, and M.D. Blaufox Nuclear medicine studies of the prostate, testes, and bladder Semin Nucl Med 36 2006 51 72 (Pubitemid 41779367)
12. W. Langsteger, M. Heinisch, and I. Fogelman The role of fluorodeoxyglucose, 18Fdihydroxyphenylalanine, 18Fcholine, and 18F-fluoride in bone imaging with emphasis on prostate and breast Semin Nucl Med 36 2006 73 92 (Pubitemid 41782168)
13. D.T. Schmidt, H. John, and R. Zweifel Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 2005 623 628 (Pubitemid 40571106)
14. S.A. Kwee, H. Wei, and I. Sesterhenn Localization of primary prostate cancer with dual-phase 18FFluorocholine PET J Nucl Med 47 2006 262 269 (Pubitemid 46780891)
15. M. Heinisch, A. Dirisamer, and W. Loidl Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/mL? Mol Imaging Biol 8 2006 43 48 (Pubitemid 44193401)
16. M. Cimitan, R. Bortolus, and S. Morassut [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 2006 1387 1398 (Pubitemid 44885404)
17. G. Giovacchini, M. Picchio, E. Coradeschi, V. Bettinardi, L. Gianolli, and V. Scattoni Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 2010 301 309 [Epub 2009 September 15]
18. A.P. Kirkham, M. Emberton, and C. Allen How good is MRI at detecting and characterizing cancer within the prostate? Eur Urol 50 2006 1163 1175 (Pubitemid 44692933)
19. A. Prando, J. Kurhanewicz, A.P. Borges, E.M. Oliveira Jr., and E. Figueiredo Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience Radiology 236 2005 903 910 (Pubitemid 41170854)
20. A. Sciarra, V. Panebianco, and S. Salciccia Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer Eur Urol 54 2008 589 600
21. T. Sella, L.H. Schwartz, and P.W. Swindle Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging Radiology 231 2004 379 385 (Pubitemid 38552892)
22. S. Cirillo, M. Petracchini, and L. Scotti Endorectal magnetic resonance imaging at 1.5 T to assess local recurrence following radical prostatectomy using T2-weighted and contrast enhanced imaging Eur Radiol 19 2009 761 769
23. P.J. De Visschere, G.O. De Meerleer, J.J. Fütterer, and G.M. Villeirs Role of MRI in follow-up after focal therapy for prostate carcinoma AJR Am J Roentgenol 194 2010 1427 1433
24. D. Yakar, T. Hambrock, H. Huisman, C.A. Hulsbergen-van de Kaa, E. van Lin, and H. Vergunst Feasibility of 3 T dynamic contrast enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy Invest Radiol 45 2010 121 125
25. F.V. Coakley, H.S. The, and A. Qayyum Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience Radiology 233 2004 441 448 (Pubitemid 39423803)
26. M.A. Haider, P. Chung, and J. Sweet Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy Int J Radiat Oncol Biol Phys 70 2008 425 430
27. O. Rouviere, O. Valette, and S. Grivolat Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings Urology 63 2004 922 927 (Pubitemid 38596680)
28. A.C. Westphalen, F.V. Coakley, M. Roach 3rd, C.E. McCulloch, and J. Kurhanewicz Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection Radiology 256 2010 485 492
29. M. Eiber, A.J. Beer, K. Holzapfel, R. Tauber, C. Ganter, and G. Weirich Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging Invest Radiol 45 2010 15 23
30. C. Testa, R. Schiavina, R. Lodi, E. Salizzoni, B. Corti, and B. Barbiroli Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT Radiology 244 2007 797 806 (Pubitemid 47292091)
31. H. Watanabe, M. Kanematsu, H. Kondo, N. Kako, N. Yamamoto, and T. Yamada Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging J Magn Reson Imaging 31 2010 1151 1156
32. V. Scattoni, M. Roscigno, M. Raber, P. Consonni, L. Da Pozzo, and P. Rigatti Biopsy of the vesico-urethral anastomosis after radical prostatectomy: when and how Eur Urol 38 Suppl 1 2002 89 95 (Pubitemid 36056450)
33. J.A. Connolly, K. Shinohara, J.C. Presti Jr., and P.R. Carroll Local recurrence after radical prostatectomy. Characteristics in size, location, and relationship to prostatespecific antigen and surgical margins Urology 47 1996 225 231 (Pubitemid 26075278)
34. J.J. Fütterer, S.W. Heijmink, T.W. Scheenen, J. Veltman, H.J. Huisman, and P. Vos Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging Radiology 241 2 2006 449 458 (Pubitemid 44632891)
35. M.D. Saleem, H. Sanders, M. Abu El Naser, and R. El-Galley Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy Urology 51 1998 283 286 (Pubitemid 28093182)
36. V. Scattoni, F. Montorsi, M. Picchio, M. Roscigno, A. Salonia, and P. Rigatti Diagnosis of local recurrence after radical prostatectomy BJU Int 93 5 2004 680 688 (Pubitemid 38375788)
37. B.J. Krause The detection rate of [11C]choline-PET/CT depends on the serum PSA value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 1 (January) 2008 18 23 (Pubitemid 350234152)